Compare General Dynamics Corporation (GD) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Novartis AG — how do they compare? General Dynamics Corporation trades at $327.41 (market cap $89.26B), while Novartis AG trades at $143.34 (market cap $268.57B). The key difference: Novartis AG is far larger — about 3× General Dynamics Corporation's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold General Dynamics Corporation for 85 Days and Novartis AG for 82 Days on average.
| GD | NVS | |
|---|---|---|
Market Cap | $89.26B | $268.57B |
Volume | 1,496,273 | 1,532,573 |
Sector | Industrials | Health |
52-Week High | $395.97 | $168.62 |
52-Week Low | $312.53 | $121.80 |
Typical Hold Time | 85 Days | 82 Days |
Enterprise Value | $94.40B | $309.89B |
Dividend Yield | 1.93% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $326.63, down 1.42% amid bearish technical signals, though fundamentals remain solid with consistent earnings beats and strong defense contract visibility. The stock shows oversold RSI readings while maintaining healthy profitability metrics including 8.18% net margin and 17.8% ROE. Recent Pentagon spending focus and dividend stability support the investment case despite near-term price pressure.
GD presents a compelling value opportunity with 57% analyst buy ratings and $420.57 consensus target representing 29% upside. Defense budget tailwinds and submarine/vehicle demand provide growth catalysts, though technical weakness and defense sector volatility pose near-term risks. The company's consistent cash flow generation and dividend payments offer stability for long-term investors.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
